Skip to main content
PMC home page
Molecular Medicine logoLink to Molecular Medicine
. 2020 Dec 9;26:123. doi: 10.1186/s10020-020-00245-4

Variant in NHLRC2 leads to increased hnRNP C2 in developing neurons and the hippocampus of a mouse model of FINCA disease

Anniina E Hiltunen 1,2,✉, Salla M Kangas 1,2, Steffen Ohlmeier 3, Ilkka Pietilä 1,4, Jori Hiltunen 1, Heikki Tanila 5, Colin McKerlie 6,7, Subashika Govindan 8, Hannu Tuominen 9,10, Riitta Kaarteenaho 11,12, Mikko Hallman 1, Johanna Uusimaa 1,13, Reetta Hinttala 1,2
PMCID: PMC7724728  PMID: 33297935

Abstract

Background

FINCA disease is a pediatric cerebropulmonary disease caused by variants in the NHL repeat-containing 2 (NHLRC2) gene. Neurological symptoms are among the first manifestations of FINCA disease, but the consequences of NHLRC2 deficiency in the central nervous system are currently unexplored.

Methods

The orthologous mouse gene is essential for development, and its complete loss leads to early embryonic lethality. In the current study, we used CRISPR/Cas9 to generate an Nhlrc2 knockin (KI) mouse line, harboring the FINCA patient missense mutation (c.442G > T, p.Asp148Tyr). A FINCA mouse model, resembling the compound heterozygote genotype of FINCA patients, was obtained by crossing the KI and Nhlrc2 knockout mouse lines. To reveal NHLRC2-interacting proteins in developing neurons, we compared cortical neuronal precursor cells of E13.5 FINCA and wild-type mouse embryos by two-dimensional difference gel electrophoresis.

Results

Despite the significant decrease in NHLRC2, the mice did not develop severe early onset multiorgan disease in either sex. We discovered 19 altered proteins in FINCA neuronal precursor cells; several of which are involved in vesicular transport pathways and actin dynamics which have been previously reported in other cell types including human to have an association with dysfunctional NHLRC2. Interestingly, isoform C2 of hnRNP C1/C2 was significantly increased in both developing neurons and the hippocampus of adult female FINCA mice, connecting NHLRC2 dysfunction with accumulation of RNA binding protein.

Conclusions

We describe here the first NHLRC2-deficient mouse model to overcome embryonic lethality, enabling further studies on predisposing and causative mechanisms behind FINCA disease. Our novel findings suggest that disrupted RNA metabolism may contribute to the neurodegeneration observed in FINCA patients.

Keywords: FINCA, NHLRC2, hnRNP C1/C2, Crispr/Cas9, Neuronal precursor cell, 2D-DIGE

Background

FINCA disease is a progressive cerebropulmonary disease (OMIM #618278) presenting with severe tissue fibrosis, neurodegeneration, and cerebral angiomatosis caused by pathogenic variants of the NHL Repeat Containing 2 (NHLRC2) gene (Uusimaa et al. 2018; Brodsky et al. 2020). Although FINCA patients have multi-organ manifestations including chronic hemolytic anemia, neurological symptoms were among the first to appear, by 2 months of age. Neuropathology of FINCA patients identified brain atrophy, vacuolar neurodegeneration, myelin loss with gliosis, cerebral angiomatosis, and neuronal depletion of the anterior horns of the spinal cord (Uusimaa et al. 2018). NHLRC2 mRNA is present in several cell types and regions of the human and mouse brain (Zhang et al. 2014,2016). In addition, altered NHLRC2 and NHLRC2 mRNA levels have been detected in neurodegenerative diseases such as Parkinson’s disease (PD) (Dijk et al. 2012) and Alzheimer’s disease (AD) (Long et al. 2016). A wide range of neural tube-related developmental malformations called developmental duplications have been reported in Angus cattle that are homozygous for p.Val311Ala substitution in the beta-propeller domain of NHLRC2 (Denholm 2017). Despite accumulating evidence for the importance of NHLRC2 in the central nervous system, its function in neurons is currently unknown.

NHLRC2 consists of an N-terminal thioredoxin (Trx)-like domain, a six-bladed β-propeller domain, and a C-terminal β-stranded region (Biterova et al. 2018). Structural analysis of the protein has revealed a highly conserved cleft between the Trx-like and β-propeller domains that forms a possible binding site for currently unknown substrates or interaction partners (Biterova et al. 2018). Recent in vitro studies have shed some light on the possible functions of NHLRC2. FINCA patient-derived and immortalized skin fibroblasts show enhanced differentiation to myofibroblasts and variants in NHLRC2 were found to affect the cytoskeleton organization and vesicle transport in normal human dermal fibroblasts (Paakkola et al. 2018). In macrophages, NHLRC2 was discovered to be a novel regulator of phagocytosis in two genome-wide knockout (KO) screens (Haney et al. 2018; Yeung et al. 2019), and has been proposed to affect phagocytosis via its effect on actin dynamics through RhoA–Rac1 signalling (Haney et al. 2018). In colon cancer cells, loss of NHLRC2 was found to increase the susceptibility of these cells to apoptosis induced by reactive oxygen species (ROS) (Nishi et al. 2017). However, the physiological function of NHLRC2 remains elusive.

The mouse ortholog of human NHLRC2 has 84% protein sequence similarity (Uusimaa et al. 2018), and it has been proposed that the function of NHLRC2 is conserved across species (Biterova et al. 2018). The complete loss of Nhlrc2 leads to early embryonic lethality, highlighting its essential role in embryonic development (Uusimaa et al. 2018; Perez-Garcia et al. 2018; Delhotal 2016). X-gal staining has revealed widespread expression of Nhlrc2 in a variety of organs during embryonic development (Uusimaa et al. 2018). Nhlrc2 mRNA and NHLRC2 mRNA expression is especially high during early brain development in mice and humans respectively (Uusimaa et al. 2018; Cardoso-Moreira et al. 2019; Miller et al. 2014), and in situ hybridization of embryonic day 14.5 mice shows high expression in the ventricular layer of the telencephalon (Diez-Roux et al. 2011). Nhlrc2 has been detected in the transcriptional waves directing the differentiation of new born neurons in the neocortex (Telley et al. 2016). To date, molecular mechanisms related to Nhlrc2 during brain development remain unexplored.

We describe here a novel FINCA knockin (KI) mouse line, generated by editing the mouse endogenous Nhlrc2 gene to include the missense mutation identified in Finnish FINCA patients. This NHLRC2 deficient mouse escapes the embryonic lethality that has previously prevented further in vivo studies of a fully null KO mouse line. We compared the proteomes of FINCA and wild-type mouse embryonic neuronal precursor cells (NPCs), to elucidate the effect of NHLRC2 deficiency on developing neurons of the neocortex. The results obtained from our studies contribute to an understanding of the pathological mechanisms leading to neurodegeneration in FINCA disease.

Materials and methods

A detailed description of the materials and methods is found in the Additional File 1. Unedited full images of the immunoblots are presented in Additional File 2.

Results

The first mouse model for FINCA has significantly decreased NHLRC2 protein levels but normal tissue histology

FINCA disease is caused by pathogenic variants in Nhlrc2. The mutation site and its adjacent area are highly conserved between human and mouse (Fig. 1a). We generated a mouse line with the FINCA patient variant c.442G > T by editing the mouse endogenous Nhlrc2 gene using the CRISPR/Cas9 method (Cong et al. 2013; Mali et al. 2013; Inui et al. 2014) (Fig. 1a, Additional File 1: Fig. S1). The heterozygous FINCA (hereafter Nhlrc2FINCA/+) and heterozygous Nhlrc2 KO, C57BL/6N-Atm1BrdNhlrc2tm1a(KOMP)Wtsi/WtsiOulu (hereafter Nhlrc2−/+) (Skarnes et al. 2011) mice were crossed to obtain mice (Nhlrc2FINCA/−) mimicking the genotype of compound heterozygote FINCA patients with the missense variant and a frameshifting nonsense variant on the other allele (Uusimaa et al. 2018).

Fig. 1.

Fig. 1

Open in a new tab

Schematic of the generated FINCA allele and body weight curve of Nhlrc2FINCA/− and Nhlrc2+/+ mice. a Modified region of mouse and human amino acid (aa) and nucleotide sequence (nt) of the modified region. Silent mutation leading to removal of the PAM site and resulting in the addition of a TatI restriction site (green) was included in the ssODN. FINCA variant c.442G > T (red) and amino acid substitution p.Asp148Tyr (yellow) are shown. b Body weight curve showing no significant difference in weight gain for either sex between Nhlrc2FINCA/− and Nhlrc2+/+ mice during the 32- week observation period (two-way ANOVA). Nhlrc2FINCA/− male (N = 6), Nhlrc2+/+ male (N = 6) Nhlrc2FINCA/− female (N = 6) Nhlrc2+/+ female (N = 5). Mean and standard deviation (SD) shown

Immunoblotting with NHLRC2 antibody recognized a band corresponding to the predicted size of mouse NHLRC2 (78.43 kDa, Uniprot.org, 25.3.20), showing a consistent decrease in all Nhlrc2FINCA/− mouse tissues evaluated (Fig. 1, Additional File 1: S2). As in humans, NHLRC2 protein was present in all analysed mouse tissue homogenates (Additional File 1: Fig. S2). Compound heterozygous Nhlrc2FINCA/− mice had a more prominent decrease in the amount of NHLRC2 compared to homozygous Nhlrc2FINCA/FINCA mice (Additional File 1: Fig. S3). We selected a set of tissues affected by FINCA disease (hippocampus, cerebellum, brainstem, lung, liver) and determined the amount of NHLRC2 protein in the Nhlrc2FINCA/− mice. NHLRC2 was decreased to 1.1% in the hippocampus (p < 0.0001), to 3.3% (p < 0.0001) in the cerebellum, and to 6.2% (p = 0.0004) in the brainstem of Nhlrc2FINCA/− mice compared to wild-type mice (Fig. 2). Nhlrc2FINCA/− mouse lung and liver lysates had 1.7% (p = 0.011) and 3.2% (p < 0.0001) of residual NHLRC2, respectively, compared to Nhlrc2+/+ mice (Fig. 2).

Fig. 2.

Fig. 2

Open in a new tab

NHLRC2 is significantly decreased in Nhlrc2FINCA/− mouse tissues. SDS-PAGE immunoblotting showing NHLRC2 in hippocampus, cerebellum, and brainstem of 13-week-old and lung and liver of 32-week-old Nhlrc2FINCA/− and Nhlrc2+/+ mouse tissue lysates. The amount of NHLRC2 decreased to 1.1% in the hippocampus (p < 0.0001), 3.3% in the cerebellum (p < 0.0001), 6.2% (p = 0.0004) in the brainstem, 3.2% (p < 0.0001) in the liver, and 1.7% (p = 0.011) in the lung of Nhlrc2 FINCA/− mice compared to wild-type mice (Student’s t-test). The expected size of full length NHLRC2 is 78.4 kDa. Protein amounts are relative to one of the wild-type samples, and GAPDH was used for normalization. Dot blots show individual data points, group mean and standard error of the mean (SEM). ****p < 0.0001, ***p < 0.001

Compound heterozygous Nhlrc2FINCA/− mice (6 males and 6 females) and their wild-type Nhlrc2+/+ litter mates (6 males and 5 females) were observed for 32 weeks. Nhlrc2 FINCA/− mice appeared normal at birth, gained weight comparably to wild-type litter mates (Fig. 1b), and reproduced normally (Additional File 1: Table S3). Nhlrc2FINCA/− mice did not develop clinical signs during the observation period, and they were euthanized for tissue-based evaluation of FINCA disease-like phenotype. There was no brain atrophy or abnormal histology identified in hippocampal and cerebellar sections of Nhlrc2FINCA/− mice (Fig. 3). Lung and liver fibrosis and hemolytic anemia are also common manifestations of FINCA disease (Uusimaa et al. 2018; Brodsky et al. 2020). There were no observable abnormalities in lung and liver sections of Nhlrc2FINCA/− mice (Additional File 1: Fig. S4), nor were there significant changes in hemoglobin or hematocrit values (Additional File 1: Table S4).

Fig. 3.

Fig. 3

Open in a new tab

Nhlrc2FINCA/− mice showed no morphological changes, neurodegeneration, or demyelination in the brain. a Upper: Representative image of 32-week-old female Nhlrc2FINCA/− and Nhlrc2+/+ hippocampal section stained with Luxol fast blue. Lower: a higher magnification showed no neurodegeneration in the dorsal hippocampus. b Upper: Representative image of 32-week-old male Nhlrc2FINCA/− and Nhlrc2+/+ cerebella. Lower: Higher magnification of the area inside the red box showing normal granule and Purkinje cells (black arrow). c Dot blots showing brain weight after fixation; area of the hippocampal section and thickness of corpus callosum measured from the midline. Individual datapoints, means and SEM are shown. There were no significant changes (Student’s t-test)

Although Nhlrc2FINCA/− mice did not recapitulate the tissue manifestations of FINCA disease, the decrease in NHLRC2 protein at the tissue level is striking. Thus, our Nhlrc2FINCA/− mouse model enables studies of the changes at the molecular and cellular level resulting from decreased NHLRC2. This may reveal the affected pathways that predispose and ultimately lead to a severe disease phenotype.

Characterization of Nhlrc2FINCA/− embryonic NPCs

To study developing neurons, we established cortical NPC cultures from E13.5 embryos from heterozygous Nhlrc2FINCA/+ and Nhlrc2−/+ matings. Nhlrc2FINCA/− embryos appeared indistinguishable from wild-type littermates, and the NPCs grew normally in vitro without any apparent phenotype (Additional File 1: Fig. S5). The amount of NHLRC2 was decreased to 5% (p < 0.0001) in Nhlrc2FINCA/− NPCs compared to wild-type cells (Fig. 4a). Heterozygosity in either the FINCA or KO allele led to a significant change in protein level, to 53% (p = 0.0062) and 37% (p = 0.0009), respectively (Fig. 4a).

Fig. 4.

Fig. 4

Open in a new tab

Nhlrc2FINCA/− mouse NPCs display a significant decrease in Nhlrc2 expression and in the amount of NHLRC2. a Immunoblotting and scatter plot of band intensities of NHLRC2 in four Nhlrc2+/+, four compound heterozygous Nhlrc2FINCA/−, three heterozygous Nhlrc2FINCA/+, and three heterozygous Nhlrc2+/−  NPC whole-cell lysates. Nhlrc2FINCA/− (5%, p < 0.0001), Nhlrc2FINCA/+ (53%, p = 0.0062), and Nhlrc2+/− (37%, p = 0.0009) had significantly decreased NHLRC2 levels compared to wild-type NPCs. Nhlrc2FINCA/− also differed significantly from Nhlrc2FINCA/+ (p = 0.0007) and Nhlrc2+/− (p = 0.039) (Student’s t-test). Protein amounts are relative to one of the wild-type samples and GAPDH was used for normalization. b qPCR from four Nhlrc2FINCA/− and four Nhlrc2+/+ showed 50.2% mRNA expression (p = 0.0005) in the Nhlrc2FINCA/− NPCs when using primers designed over the intron between exons 4 and 5 of Nhlrc2, where the KO first allele construct resides and terminates the transcription. c qPCR, using a primer pair over the intron between exons 3 and 4 of Nhlrc2, from three Nhlrc2FINCA/− and three Nhlrc2+/+ NPCs, showed a significant decrease in Nhlrc2FINCA\− (70%, p = 0.0044) cells compared to Nhlrc2+\+ (Student’s t-test). Scatter plots show individual data points, group means, and SEM. ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05

The LacZ cassette of the KO allele, Nhlrc2tm1a(KOMP)Wtsi, resides in the intron between exons 4 and 5 of Nhlrc2, where it leads to the termination of transcription. Since KO first conditional-ready tma1 alleles can skip over the LacZ cassette and restore the original gene expression to some extent (White et al. 2013), we compared the expression prior to and after the LacZ site by quantitative polymerase chain reaction (qPCR) using primers preceding and primers overlapping the intronic area with the cassette. qPCR preceding the cassette resulted in 70% Nhlrc2 mRNA in Nhlrc2FINCA/− NPCs compared to expression levels in wild-type NPCs (p = 0.004) (Fig. 4c). The expression of the full-length Nhlrc2 mRNA was 50.2% in the Nhlrc2FINCA/− NPCs compared to wild-type NPCs (p = 0.0005) (Fig. 4b). Similarly, the full-length Nhlrc2 mRNA was decreased to 50% in immortalized FINCA patient fibroblast expressing only the missense variant (Uusimaa et al. 2018). Collectively, this suggests that Nhlrc2 mRNA encoding p.Asp148Tyr is stable both in humans and in mice. The KO allele of Nhlrc2tm1a(KOMP)Wtsi retains 20% expression of the truncated protein with LacZ without a sign of leakage of the full-length Nhlrc2.

2D-DIGE revealed 19 proteins affected by Nhlrc2FINCA/− genotype in embryonic cortical NPCs

To further study the effect of NHLRC2 deficiency on developing neurons, we compared Nhlrc2FINCA/− and Nhlrc2+/+ NPCs with two-dimensional difference gel electrophoresis (2D-DIGE). 2D-DIGE revealed 21 spots with significantly changed intensities between the two genotypes (Additional File 1: Fig. S6). Further analysis using mass spectrometry (MS) identified 19 unique proteins (Table 1, Additional File 1: Table S5). Among them, only the transitional endoplasmic reticulum ATPase (VCP) was decreased in Nhlrc2FINCA/− NPCs, whereas all other proteins were increased in the mutant in comparison to Nhlrc2+/+ NPCs.

Table 1.

List of significantly changed proteins from 2D-DIGE identified by MS (p < 0.05, minimum 1.5-fold change)

Spot Protein Description Ratio t-Test
1 VCP Transitional endoplasmic reticulum ATPase − 2.07 0.01
2 ANXA6 Annexin A6 1.85 0.04
3 PLS3 Plastin-3 1.62 0.05
4 SNX6 Sorting nexin-6 1.62 0.02
5 hnRNP C1/C2 Heterogeneous nuclear ribonucleoprotein C1/C2 (isoform C2) 1.54 0.03
6 UBL7 Ubiquitin-like protein 7 1.95 0.04
7 GPD1L Glycerol-3-phosphate dehydrogenase 1-like protein (isoform 1 or 2) 1.54 0.03
8 TIMM29 Mitochondrial import inner membrane translocase subunit Tim29 1.57 0.03
9 UBA1 Ubiquitin-like modifier-activating enzyme 1 (C-terminal fragment) 2.45 0.04
10 PRDX6 Peroxiredoxin-6 1.90 0.01
11 PSMA2 Proteasome subunit α type-2 1.66 0.04
12 FTL1 Ferritin light chain 1 1.77 0.04
13 RBM8A RNA-binding protein 8A (isoform 1) 1.60 0.05
14 FTL1 Ferritin light chain 1 (N-terminal fragment) 2.14 0.02
15 PFDN2 Prefoldin subunit 2 1.68 0.05
16 HIST1H4A Histone H4 1.62 0.03
17 HIST1H4A Histone H4 2.89 0.03
18 DYNLRB1 Dynein light chain roadblock-type 1 1.68 0.04
19 ABRACL Costars family protein ABRACL 1.63 0.04
20 PEA15 Astrocytic phosphoprotein PEA-15 (isoform 1) 2.04 0.04
21 BRK1 Protein BRICK1 1.81 0.03
Open in a new tab

The ratio indicates the change of the normalized spot volumes in Nhlrc2FINCA/− in comparison to Nhlrc2+/+ NPCs

STRING protein–protein interaction analysis

Protein–protein interaction analysis of the changed mouse proteins observed in 2DE-DIGE, and their human orthologs, showed significant enrichment of interaction for the identified proteins (mouse p = 0.00056 and human p = 0.00204) (Additional File 1: Fig. S7). Interestingly, VCP was found to be a central node in both networks; however, our further qPCR, SDS-PAGE, and immunoblotting experiments failed to show significant differences between Nhlrc2FINCA/− and Nhlrc2+/+ NPCs (Additional File 1: Table S6, Fig. S8). Collectively, this suggests that the observed change for VCP is the result of an additional posttranslational modification which, in turn, might hinder detection with the antibodies.

NHLRC2 affects proteins enriched in vesicular compartments

Gene ontology (GO) enrichment analysis of human orthologs for cellular components revealed that the majority of changed proteins were linked to extracellular exosomes, vesicles, and protein-containing complexes, as well as cytosol (Table 2). No enrichment was found in certain molecular functions or biological processes in the GO term analysis. Similarly, NHLRC2 has previously been linked to an exceptionally large variety of biological processes (Paakkola et al. 2018; Haney et al. 2018; Yeung et al. 2019).

Table 2.

Gene ontology enrichment analysis of human orthologs of the identified genes

GO cellular component complete Homo sapiens REFLIST (20,996) Observed (19) Expected Fold enrichment  ±  Raw p-value FDR
Azurophil granule lumen (GO:0035578) 90 3 0.08 36.84  +  7.72E−05 1.94E−02
 → Azurophil granule (GO:0042582) 154 3 0.14 21.53  +  3.63E−04 4.86E−02
  → Vesicle (GO:0031982) 3868 11 3.5 3.14  +  1.45E−04 2.92E−02
Primary lysosome (GO:0005766) 154 3 0.14 21.53  +  3.63E−04 4.56E−02
 → Lysosome (GO:0005764) 708 6 0.65 9.3  +  2.91E−05 9.73E−03
  → Lytic vacuole (GO:0000323) 708 6 0.65 9.3  +  2.91E−05 1.17E−02
  → Vacuole (GO:0005773) 809 6 0.74 8.14  +  6.10E−05 1.75E−02
Secretory granule lumen (GO:0034774) 320 4 0.29 13.81  +  1.79E−04 3.27E−02
 → Cytoplasmic vesicle lumen (GO:0060205) 324 4 0.29 13.64  +  1.88E−04 3.14E−02
  → Vesicle lumen (GO:0031983) 326 4 0.3 13.56  +  1.92E−04 2.97E−02
Extracellular exosome (GO:0070062) 2098 10 1.9 5.27  +  3.98E−06 7.99E−03
 → Extracellular vesicle (GO:1903561) 2119 10 1.92 5.21  +  4.36E−06 4.37E−03
  → Extracellular organelle (GO:0043230) 2124 10 1.92 5.2  +  4.45E−06 2.98E−03
 → Extracellular space (GO:0005615) 3349 10 3.03 3.3  +  2.45E−04 3.51E−02
Cytosol (GO:0005829) 5229 14 4.76 2.94  +  1.21E−05 6.08E−03
Protein-containing complex (GO:0032991) 5520 13 5.03 2.58  +  1.59E−04 3.55E−02
Open in a new tab

Presented hierarchically with the most specific subclass first, with its parent terms directly below it. Related classes in an ontology are grouped. Results shown for false discovery rate (FDR) < 0.05. (geneontology.org, 22.5.20)

Heterogeneous nuclear ribonucleoprotein C1/C2 is increased in NPCs and in the hippocampus of adult Nhlrc2FINCA/− mice

We next performed qPCR to study whether the changes observed in 2D-DIGE could be explained by changes in transcription. Only three of the identified proteins, annexin A6 (ANXA6), ferritin light chain 1 (FTL1), and heterogeneous nuclear ribonucleoproteins C1/C2 (hnRNP C1/C2), had significantly changed transcriptional levels in Nhlrc2FINCA/− NPCs (Fig. 5a and Additional File 1: Table S6). Contrary to the increased intensity observed in 2D-DIGE, the expression of these genes was decreased. Anxa6 had 75% (p = 0.023), Ftl1 80% (p = 0.035), and Hnrnpc 70% (p = 0.012) expression in mutant NPCs compared to the wild-type NPCs. Hence, the changes in 2D-DIGE are likely to be differences in the protein turnover rates or in the chemical and physical properties of the proteins, caused by, for example, changes in their post-translational modifications (PTMs), rather than differences in their expression.

Fig. 5.

Fig. 5

Open in a new tab

qPCR and immunoblotting showed changes in the hnRNPC C2 level in NPCs and hippocampus of Nhlrc2FINCA/− mouse. a qPCR results of the three protein transcripts; Ftl1, Anxa6, and Hnrnpc, showed significantly changed RNA levels in Nhlrc2FINCA/− (square) compared to Nhlrc2+/+ (round) NPCs, 80% (p = 0.035), 75%, (p = 0.023), and 70% (p = 0.012) respectively (Student’s t-test). Expression was normalized against one wild-type sample. Individual data points, group mean, and SEM are shown. b SDS-PAGE immunoblot and measured protein levels of three Nhlrc2 −/− and Nhlrc2FINCA/− NPC lysates revealed increased hnRNP C2 (165% p = 0.045). c SDS-PAGE immunoblot and measured protein levels from 13-week-old female Nhlrc2FINCA/− and wild-type hippocampal tissue lysates showed increased hnRNP C2 (820%, p = 0.046). hnRNP C2-specific antibody was used and the expected size of hnRNP C2 is 34.4 kDa. d SDS-PAGE immunoblot and measured protein levels from 5-week-old male Nhlrc2FINCA/− and wild-type hippocampal tissue lysates for myelin basic protein (MBP) and myelin associated glycoprotein (MAG). MAG was significantly decreased in Nhlrc2FINCA/− (69%, p = 0,027). Protein amounts are relative to one of the wild-type samples and GAPDH was used for normalization. Individual data points, group mean, and SEM are shown. Statistical analysis was done using Student's t-test *p < 0.05

HnRNP C1/C2, isoform C2 showed elevated protein levels in Nhlrc2FINCA/− compared to Nhlrc2+/+ NPCs in the 2D-DIGE analysis (Table 1), whereas qPCR indicated decreased mRNA levels (Fig. 5a and Additional File 1: Table S6). SDS-PAGE and immunoblotting confirmed the observed changes at the protein level with a 65% increase in Nhlrc2FINCA/− NPCs (p = 0.045) (Fig. 5b). Immunocytochemistry (ICC) staining indicated normal localization of hnRNP C1/C2 in both mutant and wild-type cells (Additional File 1: Fig. S9).

In situ hybridization (ISH) of Nhlrc2 showed ubiquitous expression throughout the adult brain of 32-week-old male mice, with the most prominent expression in cerebellar granule cells, followed by granule cells in the dentate gyrus, and then by pyramidal cells in hippocampal CA1 layer and layer 2 of the piriform cortex (Fig. 6). ISH of Nhlrc2FINCA/− brain revealed a similar expression pattern of the mutated Nhlrc2 mRNA to that of the wild-type (Additional File 1: Fig. S11). Since the hippocampus, cerebellum, and brainstem are affected in FINCA disease, we performed SDS-PAGE and immunoblotting analyses of hnRNP C2 in these tissues from 13-week-old female Nhlrc2FINCA/− and Nhlrc2+/+ mice. Interestingly, hnRNP C2 (820%, p = 0.046) was observed to be significantly increased in the hippocampus of Nhlrc2FINCA/− in comparison to Nhlrc2+/+ (Fig. 5c), but not in the cerebellum or brainstem of the same animals (Additional File 1: Fig. S10). Furthermore, hnRNP C2 has been found to affect transcription of myelination related genes in human neuroblastoma cells (Iwata et al. 2011). Immunoblotting of 5-week-old mouse hippocampus lysates revealed a significant decrease in the amount of myelin-associated glycoprotein (MAG) in Nhlrc2FINCA/− mice compared to wild type mice (69%, p = 0.027) (Fig. 5d). Myelin basic protein (MBP) also showed a decrease in the amount of protein but was not statistically significant (52%, p = 0.092) (Fig. 5d). These findings associate hnRNP C2 with the FINCA disease pathology and suggest that NHLRC2 plays an important role especially in the hippocampus.

Fig. 6.

Fig. 6

Open in a new tab

Representative in situ hybridization of Nhlrc2 in the brain of a 32-week-old male C57BL/6NCrl mouse. a Overview image of ISH with Nhlrc2 probe (red). Red boxes mark the magnified areas: a CA1 layer of hippocampus, b dentate gyrus of hippocampus, c piriform cortex, d cerebellar hemisphere. b Nhlrc2 expression in areas a–d. A strong signal was observed from the pyramidal cell layer of the hippocampus and piriform cortex as well as dentate and cerebellar granule cells. c Negative control from areas a–d

Discussion

KI mouse models can be considered precision disease models that recapitulate the single pathogenic variant created into the endogenous target gene, omitting any artificial overexpression of gene products seen in conventional transgenic mouse models. Here, we generated a KI mouse line with the FINCA patient variant c. 442G < T, p.Asp148Tyr, in the endogenous mouse Nhlrc2 gene. By crossing this mouse line with the Nhlrc2 KO mouse line, we produced a similar compound heterozygous genotype to that identified in FINCA patients. Compound heterozygous Nhlrc2FINCA/− mice overcame the embryonic lethality of Nhlrc2 KO mice and developed normally in utero. Since the missense mutation does not reside in the most evolutionarily conserved area of NHLRC2 that is predicted to be the active core of the protein (Biterova et al. 2018), the p.Asp148Tyr NHLRC2 may have retained some of its physiological activity, allowing normal embryonic development both in humans and mice. Nhlrc2FINCA/− mice retained 5% residual NHLRC2 throughout the body, including NPCs.

We compared the proteomes of Nhlrc2FINCA/− and Nhlrc2+/+ NPCs to study the functional processes affected by NHLRC2 deficiency in developing neurons. Proteomics identified 19 proteins that were significantly affected by the Nhlrc2FINCA/− genotype. Cellular compartment GO enrichment analysis of the altered proteins revealed a strong association with vesicles, extracellular exosomes, protein-containing complexes, and cytosol. Consistent with our findings, NHLRC2 has been connected previously to forms of endocytosis, such as phagocytosis (Haney et al. 2018; Yeung et al. 2019) and multivesicular transportation (Paakkola et al. 2018) in other cell types, and when mutated, could lead to pathological aggregation of proteins. Neurodegenerative diseases are often characterized by protein aggregates, and, not surprisingly, mutations in endo- and autolysosomal pathway genes have been associated with several neurodegenerative disorders, such as AD, PD, and lysosomal storage disease (Wang et al. 2018; Menzies et al. 2015). Neurons aim to remove the accumulated proteins through an endosomal pathway by lysosomal degradation or by releasing them into the extracellular space via multivesicular bodies and exosomes (Kalani et al. 2014). In addition to the late-onset storage diseases mentioned above, there are neurodevelopmental disorders with multisystemic involvement where autophagy impairment has been implicated, such as Vici syndrome (Hori et al. 2017) and Rett syndrome (Sbardella et al. 2017), which partly resemble FINCA disease. Collectively, the dysfunction in vesicular trafficking may create a predisposition to neurodegeneration in FINCA disease.

The proteomic approach we used resulted not only in the identification of changes in the amount of proteins in vitro, but it also provided further information about the characteristics of these proteins revealing the presence of altered isoforms (hnRNP C2, RBM8A, PEA15) as well as fragments (UBA1, FTL1). This suggests that additional regulatory mechanisms apart from transcription and translation, such as alternative splicing, PTM, or different turnover rates may play a role in FINCA disease pathology. Whereas isoforms can have different functions, PTMs regulate protein folding or activity, subcellular targeting, and interaction with ligands or other proteins (Burkle 2001), among other functions. In this study, VCP was the only spot that showed decreased intensity in Nhlrc2FINCA/− NPCs by proteomic analysis, and it was a central node in the protein–protein interaction analysis. Although the interaction analysis may include theoretical interactions that have not been confirmed by experimental evidence, these results made VCP an interesting hit. However, several VCP antibodies failed to recognize the spot identified by MS. This may suggest we identified a change in a specific VCP form, possibly resulting from a PTM, which changes the motility of VCP in 2D electrophoresis and prevents its recognition by antibodies. VCP is known to be regulated by a large number of PTMs (Hornbeck et al. 2014). Loss of the Nhlrc2 plant ortholog, suppressor of quenching 1, has been found to affect the electrophoretic mobility of plastid lipocalin, due to an unidentified protein modification (Malnoë et al. 2018). This raises the question whether VCP could be a target for such a protein modification. On the other hand, Nhlrc2FINCA/− NPCs showed a striking decrease in the amount of NHLRC2, in contrast to a more modest decrease in Nhlrc2 mRNA expression. The introduction of the Tyr residue has been proposed to disrupt hydrogen bonding which may destabilize the conformation of the mutated NHLRC2 (Biterova et al. 2018). Mutated NHLRC2 seems to be unstable in vivo and would need to be degraded. VCP is a well-known player in the ubiquitin–proteasome pathway (Ye et al. 2005), and the decrease in VCP spot intensity could result from changes in PTMs of VCP required for the degradation of the mutated NHLRC2. Mutations in VCP have been connected to neurodegenerative multisystemic proteinopathies in humans, such as inclusion body myopathy with Paget disease of bone and frontotemporal dementia (IBMPBFD) (Kimonis et al. 2000), amyotrophic lateral sclerosis (ALS) (Johnson et al. 2010), and Charcot-Marie-Tooth disease type 2 (CMT2) (Gonzalez et al. 2014). VCP is involved in a large number of cellular processes, but it is also involved in endo- (Ritz et al. 2011; Ramanathan and Ye 2012; Pleasure et al. 1993) and autophagic pathways (Ju and Weihl 2010). Interestingly, VCP deficiency leads to accumulation of immature autophagic vesicles (Ju et al. 2009; Tresse et al. 2010), and IBMPFD patient myoblasts accumulate large LAMP-1 and LAMP-2 positive vacuoles and LC3-II (Tresse et al. 2010). LAMP-1 positive multilamellar bodies have also been detected in electron microscopy images of immortalized FINCA patient fibroblasts (Paakkola et al. 2018).

Anxa6, Ftl1, and Hnrnpc showed significant but opposite changes in mRNA levels out of the 19 proteins identified by proteomics analysis. This kind of discrepancy between mRNA and protein levels has been observed in numerous studies (Abdulghani et al. 2019; Poverennaya et al. 2017) and reflects the independent but most often compensatory regulatory mechanisms of transcription and translation. For Hnrnpc, the lower mRNA level could also be explained by autoregulation of its own translation, which has been described for several hnRNP family members (Wollerton et al. 2004; McGlincy et al. 2010; Buratti and Baralle 2011; Rossbach et al. 2009; Müller-McNicoll et al. 2019). The increase in the hnRNP C2 protein in Nhlrc2FINCA/− embryonic NPCs and adult mouse hippocampus suggests a perturbation in overall RNA metabolism, which in turn may contribute to the neurodegeneration seen in FINCA disease. HnRNP C1/C2 is part of the hnRNP family, which is a large RNA-binding family contributing to multiple aspects of nucleic acid metabolism. Dysregulation of RNA homeostasis has been suggested as a common feature of neurodegenerative diseases, where RNA-binding proteins (RBPs) play a crucial role (Wolozin and Ivanov 2019; Conlon and Manley 2017). RBPs often have low-complexity domains, which are thought to facilitate stress and P body formation, but also make RBPs prone to self-aggregate (March et al. 2016). VCP, in contrast, has been shown to function in the clearance of stress and P bodies (Buchan et al. 2013). hnRNPs have been recognized in several common late-onset neurodegenerative diseases, such as spinal muscular atrophy (SMA), ALS, AD, and frontotemporal dementia (Wolozin and Ivanov 2019; Geuens et al. 2016; Purice and Taylor 2018). Interestingly, an increase in hnRNP C2 was detected in the hippocampus of adult Nhlrc2FINCA/− mice, but not in the cerebellum or brainstem. The hippocampal CA1 pyramidal cell layer was also one of the brain regions of adult mice with the highest expression of Nhlrc2 according to our ISH data. Altogether, this data suggests that NHLRC2 may play an important role in hippocampal pyramidal cells, which were also affected by neurodegeneration in FINCA patients (Uusimaa et al. 2018).

KI models often show a milder phenotype than human patients (Dawson et al. 2018). Here, the Nhlrc2FINCA/− mice showed normal growth compared to their wild-type litter mates and did not develop a severe disease phenotype as described in FINCA patients. Environmental factors such as pathogens or the specific genetic background may play an additional role in triggering a more severe outcome of the disease in mice (Doetschman 2009; Keane et al. 2011; Qosa and Kaddoumi 2016). Interestingly, NHLRC2 has recently been connected to immunological responses via initiation of phagocytosis in human macrophages, possibly through its effect on RhoA/Rac1 signalling, which controls actin polymerization and filopodia formation (Haney et al. 2018; Yeung et al. 2019). In addition to phagocytosis, actin cytoskeleton dynamics are important for many other cellular functions requiring remodelling of plasma membrane, or biogenesis and transport of vesicular cargo, such as cell motility, cytokinesis, endocytosis, and autophagy (Anitei and Hoflack 2012). Our proteomic analysis revealed changes in several proteins connected to actin dynamics in Nhlrc2FINCA/− NPCs, including BRICK1 (Eden et al. 2002; Gautreau et al. 2004), costars family protein ABRACL (Pang et al. 2010), plastin-3 (Bretscher 1981), prefoldin subunit 2 (Tsao et al. 2006; Martin-Benito et al. 2002), and VCP (Nalbandian et al. 2012; Chan et al. 2012; Shah and Beverly 2015). Finally, Nhlrc2FINCA/− mice, housed in specific pathogen-free conditions, may have lacked an immunological component important for triggering the FINCA disease onset, where recurrent infections were present in human patients.

Conclusions

Even though mouse models of neurodegeneration seldom show the whole spectrum of the human disease, they have proven to be invaluable tools for studying the molecular pathogenesis of neurodegeneration (Dawson et al. 2018; Leung and Jia 2016). Our results suggest for the first time that the Nhlrc2FINCA/− genotype results in dysregulation of RNA homeostasis in mouse neurons, which could ultimately contribute to the pathophysiology of neurodegeneration in FINCA disease. Further studies on human neurons are still required, but our findings presented here open future possibilities in the search for treatment and diagnosis tools for FINCA and other relevant, more common neurodegenerative diseases (Samie and Xu 2014; Spilman et al. 2010; Caccamo et al. 2014; Kim et al. 2014; Cheng et al. 2015; Lugli et al. 2015). Considering the broad spectrum of manifestations of FINCA disease, including lung and liver fibrosis, chronic hemolytic anemia, and cerebral angiomatosis, the FINCA mouse model described here offers an interesting and biologically relevant research tool for a variety of future studies.

Supplementary information

10020_2020_245_MOESM1_ESM.pdf (1.7MB, pdf)

Additional file 1: Detailed description of the materials and methods, supplementary figures S1- S11, and supplementary tables S1-S6. Materials and methods include generation of FINCA mouse, used animals, genotyping, Sanger equencing, histology, blood analysis, ISH, NPC culture, 2DE-DIGE, mass spectrometry, qPCR, immunoblotting, ICC, data analysis, and statistical considerations. Fig. S1 Genotyping and Sanger sequencing of three founders obtained from microinjections of Cas9 ribonucleoprotein and ssODN into mouse zygotes. Fig. S2 SDS-PAGE immunoblotting showing decrease of NHLRC2 in different brain regions and different tissues of Nhlrc2FINCA/− mice compared to wild type mice. Fig. S3 SDS-PAGE immunoblotting comparing the amount of NHLRC2 between wildtype, homozygous Nhlrc2FINCA/FINCA and compound heterozygous Nhlrc2FINCA/− mice. Fig. S4 Representative images of Nhlrc2+/+ and Nhlrc2FINCA/− mouse lung and liver sections. Fig. S5 NPC isolation and culture. Fig. S6 Representative 2D gel of NPCs (wild type). Fig. S7 STRING network analysis of identified proteins. Fig S8 SDS-PAGE immunoblot and 2D gel immunoblotof Nhlrc2+/+ and Nhlrc2FINCA/− NPC lysates with VCP antibodies. Fig. S9 hnRNP C2 ICC image of Nhlrc2+/+ and Nhlrc2FINCA/− NPCs showing normal cellular localization. Fig. S10 SDS-PAGE immunoblotting of Nhlrc2+/+ and Nhlrc2FINCA/− cerebellum and brainstem. Fig. S11 ISH of Nhlrc2FINCA/− mouse brain. Table S1 Genotyping primers. Table S2 qPCR primers. Table S3 Genotype distribution of Nhlrc2+/+ and Nhlrc2FINCA/− mouse offspring. Table S4 Blood values of Nhlrc2+/+ and Nhlrc2FINCA/− mice. Table S5 Detailed statistical and MS data about the proteins identified from 2DE-DIGE. Table S6. qPCR results of expression levels of genes identified in 2DE-DIGE.

10020_2020_245_MOESM2_ESM.pdf (355.4KB, pdf)

Additional file 2: Unedited full images of the immunoblots for Fig. 2, Fig. 4, Fig. S2, Fig. S3, Fig S8, and Fig S10.

Acknowledgements

The authors thank Dr. Reetta Vuolteenaho, Pirjo Keränen, Riitta Vuento, Anu Myllymäki, and Hannele Härkman for their expert assistance. Biocenter Finland and the following Biocenter Oulu core facilities: Transgenic, Proteomics, Light microscopy, and Sequencing, and Laboratory Animal Centre at the University of Oulu are acknowledged for their technical support.

Abbreviations

NHLRC2

NHL repeat-containing 2

KI

Knockin

PD

Parkinson’s disease

AD

Alzheimer’s disease

Trx

Thioredoxin

KO

Knockout

ROS

Reactive oxygen species

NPC

Neuronal precursor cell

qPCR

Quantitative polymerase chain reaction

2D-DIGE

Two-dimensional difference gel electrophoresis

MS

Mass spectrometry

VCP

Transitional endoplasmic reticulum ATPase

FDR

False discovery rate

ANXA6

Annexin A6

FTL1

Ferritin light chain 1

hnRNP

Heterogeneous nuclear ribonucleoprotein

PTM

Post-translational modification

ICC

Immunocytochemistry

ISH

In situ hybridization

MAG

Myelin associated glycoprotein

MBP

Myelin basic protein

IBMPBFD

Inclusion body myopathy with Paget disease of bone and frontotemporal dementia

ALS

Amyotrophic lateral sclerosis

CMT2

Charcot-Marie-Tooth disease type 2

RBP

RNA-binding proteins

SMA

Spinal muscular atrophy

Authors’ contributions

AH was the major contributor in performing analyses, interpreting the data, and writing the manuscript; SK designed the knock-in mouse model and participated in conducting experiments and analysis of the data; SO performed proteomics analysis and interpreted the data; IP performed histopathological examination of lung and liver samples and interpretation of the data; JH carried out the blood analysis and interpretation of the results; HT performed and analysed brain histopathology; CM screened and analysed lung and liver histopathology; SG participated in establishing the in vitro methodology and interpretation of the data; HaT and RK compared tissue pathology between FINCA patient and mouse; RK, MH, JU, and RH contributed to study design, generation of the mouse model, and interpretation of the data. All authors have participated in drafting the manuscript and have approved the submitted version. All authors read and approved the final manuscript.

Funding

This work was conducted with support from the Research Council for Health of the Academy of Finland (R.H., Decision Numbers 266498, 273790, 303996 and 317711), Academy of Finland profiling programme (R.H., Decision Number 311934), the Foundation for Pediatric Research, Finland (J.U. and R.H.), Sigrid Jusélius Foundation (M.H., decision number 1024), Biocenter Oulu (J.U. and R.H.) and State Grants for Health Research, Clinic for Children and Adolescents, Oulu University Hospital, Oulu, Finland (J.U.)

Availability of data and materials

Majority of the data generated or analysed during this study are included in this published article [and its additional information files]. Further information and additional datasets are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

All animal experiments have been approved by the Regional State Administrative Agency of Southern Finland (ESAVI/5236/04.10.07/2016, ESAVI/33827/2019). Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary information accompanies this paper at 10.1186/s10020-020-00245-4.

References

  1. Abdulghani M, Song G, Kaur H, Walley JW, Tuteja G. Comparative analysis of the transcriptome and proteome during mouse placental development. J Proteome Res. 2019;18:2088–2099. doi: 10.1021/acs.jproteome.8b00970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Anitei M, Hoflack B. Bridging membrane and cytoskeleton dynamics in the secretory and endocytic pathways. Nat Cell Biol. 2012;14:11–19. doi: 10.1038/ncb2409. [DOI] [PubMed] [Google Scholar]
  3. Biterova E, Ignatyev A, Uusimaa J, Hinttala R, Ruddock LW. Structural analysis of human NHLRC2, mutations of which are associated with FINCA disease. PLoS ONE. 2018;13:e0202391. doi: 10.1371/journal.pone.0202391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bretscher A. Fimbrin is a cytoskeletal protein that crosslinks F-actin in vitro. Proc Natl Acad Sci USA. 1981;78:6849–6853. doi: 10.1073/pnas.78.11.6849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brodsky NN, Boyarchuk O, Kovalchuk T, Hariyan T, Rice A, Ji W, et al. Novel compound heterozygous variants in NHLRC2 in a patient with FINCA syndrome. J Hum Genet. 2020 doi: 10.1038/s10038-020-0776-0. [DOI] [PubMed] [Google Scholar]
  6. Buchan JR, Kolaitis RM, Taylor JP, Parker R. Eukaryotic stress granules are cleared by autophagy and Cdc48/VCP function. Cell. 2013;153:1461–1474. doi: 10.1016/j.cell.2013.05.037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Buratti E, Baralle FE. TDP-43: new aspects of autoregulation mechanisms in RNA binding proteins and their connection with human disease. FEBS J. 2011;278:3530–3538. doi: 10.1111/j.1742-4658.2011.08257.x. [DOI] [PubMed] [Google Scholar]
  8. Burkle A. Encyclopedia of genetics. Amsterdam: Elsevier Inc.; 2001. [Google Scholar]
  9. Caccamo A, De Pinto V, Messina A, Branca C, Oddo S. Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer’s disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature. J Neurosci. 2014;34:7988–7998. doi: 10.1523/JNEUROSCI.0777-14.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Cardoso-Moreira M, Halbert J, Valloton D, Velten B, Chen C, Shao Y, et al. Gene expression across mammalian organ development. Nature. 2019;571:505–509. doi: 10.1038/s41586-019-1338-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Chan H-T, Lee T-R, Huang S-H, Lee H-Y, Sang T, Chan H-L, et al. Proteomic analysis of a drosophila IBMPFD model reveals potential pathogenic mechanisms. Mol Biosyst. 2012;8:1730–1741. doi: 10.1039/c2mb25037c. [DOI] [PubMed] [Google Scholar]
  12. Cheng L, Doecke JD, Sharples RA, Villemagne VL, Fowler CJ, Rembach A, et al. Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment. Mol Psychiatry. 2015;20:1188–1196. doi: 10.1038/mp.2014.127. [DOI] [PubMed] [Google Scholar]
  13. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339:819–823. doi: 10.1126/science.1231143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Conlon EG, Manley JL. RNA-binding proteins in neurodegeneration: mechanisms in aggregate. Genes Dev. 2017;31:1509–1528. doi: 10.1101/gad.304055.117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Dawson TM, Golde TE, Lagier-Tourenne C. Animal models of neurodegenerative diseases. Nat Neurosci. 2018;21:1370–1379. doi: 10.1038/s41593-018-0236-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Delhotal JD. Characterization of NHLRC2 gene-edited mice: a model for bovine developmental duplications. 2016.
  17. Denholm L. Genotype disclosure in the genomics era: roles and responsibilities. Aust Vet J. 2017;95:308–316. doi: 10.1111/avj.12606. [DOI] [PubMed] [Google Scholar]
  18. Diez-Roux G, Banfi S, Sultan M, Geffers L, Anand S, Rozado D, et al. A high-resolution anatomical atlas of the transcriptome in the mouse embryo. PLoS Biol. 2011;9:e1000582. doi: 10.1371/journal.pbio.1000582. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Doetschman T. Influence of genetic background on genetically engineered mouse phenotypes. Methods Mol Biol. 2009;530:423–433. doi: 10.1007/978-1-59745-471-1_23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Eden S, Rohatgi R, Podtelejnikov AV, Mann M, Kirschner MW. Mechanism of regulation of WAVE1-induced actin nucleation by Rac1 and Nck. Nature. 2002;418:790–793. doi: 10.1038/nature00859. [DOI] [PubMed] [Google Scholar]
  21. Gautreau A, Ho HYH, Li J, Steen H, Gygi SP, Kirschner MW. Purification and architecture of the ubiquitous Wave complex. Proc Natl Acad Sci USA. 2004;101:4379–4383. doi: 10.1073/pnas.0400628101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Geuens T, Bouhy D, Timmerman V. The hnRNP family: insights into their role in health and disease. Hum Genet. 2016;135:851–867. doi: 10.1007/s00439-016-1683-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Gonzalez MA, Feely SM, Speziani F, Strickland AV, Danzi M, Bacon C, et al. A novel mutation in VCP causes Charcot–Marie–Tooth Type 2 disease. Brain. 2014;137:2897–2902. doi: 10.1093/brain/awu224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Haney MS, Bohlen CJ, Morgens DW, Ousey JA, Barkal AA, Tsui CK, et al. Identification of phagocytosis regulators using magnetic genome-wide CRISPR screens. Nat Genet. 2018;50:1716–1727. doi: 10.1038/s41588-018-0254-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Hori I, Otomo T, Nakashima M, Miya F, Negishi Y, Shiraishi H, et al. Defects in autophagosome-lysosome fusion underlie Vici syndrome, a neurodevelopmental disorder with multisystem involvement. Sci Rep. 2017;7:3552. doi: 10.1038/s41598-017-02840-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, PhosphoSitePlus SE. mutations, PTMs and recalibrations. Nucleic Acids Res. 2014;2015:43. doi: 10.1093/nar/gku1267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Inui M, Miyado M, Igarashi M, Tamano M, Kubo A, Yamashita S, et al. Rapid generation of mouse models with defined point mutations by the CRISPR/Cas9 system. Sci Rep. 2014;4:5396. doi: 10.1038/srep05396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Iwata K, Matsuzaki H, Manabe T, Mori N. Altering the expression balance of hnRNP C1 and C2 changes the expression of myelination-related genes. Psychiatry Res. 2011;190:364–366. doi: 10.1016/j.psychres.2011.05.043. [DOI] [PubMed] [Google Scholar]
  29. Johnson JO, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin VM, Trojanowski JQ, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron. 2010;68:857–864. doi: 10.1016/j.neuron.2010.11.036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Ju J-S, Weihl CC. p97/VCP at the intersection of the autophagy and the ubiquitin proteasome system. Autophagy. 2010;6:283–285. doi: 10.4161/auto.6.2.11063. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Ju J-S, Fuentealba RA, Miller SE, Jackson E, Piwnica-Worms D, Baloh RH, et al. Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease. J Cell Biol. 2009;187:875–888. doi: 10.1083/JCB.200908115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Kalani A, Tyagi A, Tyagi N. Exosomes: Mediators of neurodegeneration, neuroprotection and therapeutics. Mol Neurobiol. 2014;49:590–600. doi: 10.1007/s12035-013-8544-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Keane TM, Goodstadt L, Danecek P, White MA, Wong K, Yalcin B, et al. Mouse genomic variation and its effect on phenotypes and gene regulation. Nature. 2011;477:289–294. doi: 10.1038/nature10413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Kim H-J, Raphael AR, LaDow ES, McGurk L, Weber RA, Trojanowski JQ, et al. Therapeutic modulation of eIF2α phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. Nat Genet. 2014;46:152–160. doi: 10.1038/ng.2853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Kimonis VE, Kovach MJ, Waggoner B, Leal S, Salam A, Rimer L, et al. Clinical and molecular studies in a unique family with autosomal dominant limb-girdle muscular dystrophy and Paget disease of bone. Genet Med. 2000;2:232–241. doi: 10.1097/00125817-200007000-00006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Leung C, Jia Z. Mouse genetic models of human brain disorders. Front Genet. 2016 doi: 10.3389/fgene.2016.00040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Long J, Pan G, Ifeachor E, Belshaw R, Li X. Discovery of novel biomarkers for Alzheimer’s disease from blood. Dis Markers. 2016;2016:4250480. doi: 10.1155/2016/4250480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Lugli G, Cohen AM, Bennett DA, Shah RC, Fields CJ, Hernandez AG, et al. Plasma exosomal miRNAs in persons with and without Alzheimer disease: Altered expression and prospects for biomarkers. PLoS ONE. 2015;10:e0139233. doi: 10.1371/journal.pone.0139233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-guided human genome engineering via Cas9. Science. 2013;339:823–826. doi: 10.1126/science.1232033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Malnoë A, Schultink A, Shahrasbi S, Rumeau D, Havaux M, Niyogi KK. The plastid lipocalin LCNP is required for sustained photoprotective energy dissipation in arabidopsis. Plant Cell. 2018;30:196–208. doi: 10.1105/tpc.17.00536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. March ZM, King OD, Shorter J. Prion-like domains as epigenetic regulators, scaffolds for subcellular organization, and drivers of neurodegenerative disease. Brain Res. 2016;1647:9–18. doi: 10.1016/j.brainres.2016.02.037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Martin-Benito J, Boskovic J, Gómez-Puertas P, Carrascosa JL, Simons CT, Lewis SA, et al. Structure of eukaryotic prefoldin and of its complexes with unfolded actin and the cytosolic chaperonin CCT. EMBO J. 2002;21:6377–6386. doi: 10.1093/emboj/cdf640. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. McGlincy NJ, Tan LY, Paul N, Zavolan M, Lilley KS, Smith CWJ. Expression proteomics of UPF1 knockdown in HeLa cells reveals autoregulation of hnRNP A2/B1 mediated by alternative splicing resulting in nonsense-mediated mRNA decay. BMC Genomics. 2010 doi: 10.1186/1471-2164-11-565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Menzies FM, Fleming A, Rubinsztein DC. Compromised autophagy and neurodegenerative diseases. Nat Rev Neurosci. 2015;16:345–357. doi: 10.1038/nrn3961. [DOI] [PubMed] [Google Scholar]
  45. Miller JA, Ding SL, Sunkin SM, Smith KA, Ng L, Szafer A, et al. Transcriptional landscape of the prenatal human brain. Nature. 2014;508:199–206. doi: 10.1038/nature13185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Müller-McNicoll M, Rossbach O, Hui J, Medenbach J. Auto-regulatory feedback by RNA-binding proteins. J Mol Cell Biol. 2019;11:930–939. doi: 10.1093/jmcb/mjz043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Nalbandian A, Ghimbovschi S, Radom-Aizik S, Dec E, Vesa J, Martin B, et al. Global gene profiling of VCP-associated inclusion body myopathy. Clin Transl Sci. 2012;5:226–234. doi: 10.1111/j.1752-8062.2012.00407.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Nishi K, Iwaihara Y, Tsunoda T, Doi K, Sakata T, Shirasawa S, et al. ROS-induced cleavage of NHLRC2 by caspase-8 leads to apoptotic cell death in the HCT116 human colon cancer cell line. Cell Death Dis. 2017;8:3218. doi: 10.1038/s41419-017-0006-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Paakkola T, Salokas K, Miinalainen I, Lehtonen S, Manninen A, Kaakinen M, et al. Biallelic mutations in human NHLRC2 enhance myofibroblast differentiation in FINCA disease. Hum Mol Genet. 2018;27:4288–4302. doi: 10.1093/hmg/ddy298. [DOI] [PubMed] [Google Scholar]
  50. Pang T-L, Chen F-C, Weng Y-L, Liao H-C, Yi Y-H, Ho C-L, et al. Costars, a Dictyostelium protein similar to the C-terminal domain of STARS, regulates the actin cytoskeleton and motility. J Cell Sci. 2010;123:3745–3755. doi: 10.1242/jcs.064709. [DOI] [PubMed] [Google Scholar]
  51. Perez-Garcia V, Fineberg E, Wilson R, Murray A, Mazzeo CI, Tudor C, et al. Placentation defects are highly prevalent in embryonic lethal mouse mutants. Nature. 2018;555:463–468. doi: 10.1038/nature26002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Pleasure IT, Black MM, Keen JH. Valosin-containing protein, VCP, is a ubiquitous clathrin-binding protein. Nature. 1993;365:459–462. doi: 10.1038/365459a0. [DOI] [PubMed] [Google Scholar]
  53. Poverennaya EV, Ilgisonis EV, Ponomarenko EA, Kopylov AT, Zgoda VG, Radko SP, et al. Why are the correlations between mRNA and protein levels so low among the 275 predicted protein-coding genes on human chromosome 18? J Proteome Res. 2017;16:4311–4318. doi: 10.1021/acs.jproteome.7b00348. [DOI] [PubMed] [Google Scholar]
  54. Purice MD, Taylor JP. Linking hnRNP function to ALS and FTD pathology. Front Neurosci. 2018;12:326. doi: 10.3389/fnins.2018.00326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Qosa H, Kaddoumi A. Effect of mouse strain as a background for Alzheimer’s disease models on the clearance of amyloid-β. J Syst Integr Neurosci. 2016;2:135–140. doi: 10.15761/jsin.1000123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Ramanathan HN, Ye Y. The p97 ATPase associates with EEA1 to regulate the size of early endosomes. Cell Res. 2012;22:346–359. doi: 10.1038/cr.2011.80. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Ritz D, Vuk M, Kirchner P, Bug M, Schütz S, Hayer A, et al. Endolysosomal sorting of ubiquitylated caveolin-1 is regulated by VCP and UBXD1 and impaired by VCP disease mutations. Nat Cell Biol. 2011;13:1116–1123. doi: 10.1038/ncb2301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Rossbach O, Hung L-H, Schreiner S, Grishina I, Heiner M, Hui J, et al. Auto- and cross-regulation of the hnRNP L proteins by alternative splicing. Mol Cell Biol. 2009;29:1442–1451. doi: 10.1128/mcb.01689-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Samie MA, Xu H. Thematic review series: recent advances in the treatment of lysosomal storage diseases: lysosomal exocytosis and lipid storage disorders. J Lipid Res. 2014;55:995–1009. doi: 10.1194/jlr.R046896. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Sbardella D, Tundo GR, Campagnolo L, Valacchi G, Orlandi A, Curatolo P, et al. Retention of Mitochondria in Mature Human Red Blood Cells as the Result of Autophagy Impairment in Rett Syndrome. Sci Reports. 2017;7:12297. doi: 10.1038/s41598-017-12069-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Shah PP, Beverly LJ. Regulation of VCP/p97 demonstrates the critical balance between cell death and epithelial-mesenchymal transition (EMT) downstream of ER stress. Oncotarget. 2015;6:17725–17737. doi: 10.18632/oncotarget.3918. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Skarnes WC, Rosen B, West AP, Koutsourakis M, Bushell W, Iyer V, et al. A conditional knockout resource for the genome-wide study of mouse gene function. Nature. 2011;474:337–342. doi: 10.1038/nature10163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, Bredesen D, et al. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-β levels in a mouse model of alzheimer’s disease. PLoS ONE. 2010;5:e9979. doi: 10.1371/journal.pone.0009979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Telley L, Govindan S, Prados J, Stevant I, Nef S, Dermitzakis E, et al. Sequential transcriptional waves direct the differentiation of newborn neurons in the mouse neocortex. Science. 2016;351:1443–1446. doi: 10.1126/science.aad8361. [DOI] [PubMed] [Google Scholar]
  65. Tresse E, Salomons FA, Vesa J, Bott LC, Kimonis V, Yao T-P, et al. VCP/p97 is essential for maturation of ubiquitin-containing autophagosomes and this function is impaired by mutations that cause IBMPFD. Autophagy. 2010;6:217–227. doi: 10.4161/auto.6.2.11014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Tsao M-L, Chao C-H, Yeh C-T. Interaction of hepatitis C virus F protein with prefoldin 2 perturbs tubulin cytoskeleton organization. Biochem Biophys Res Commun. 2006;348:271–277. doi: 10.1016/J.BBRC.2006.07.062. [DOI] [PubMed] [Google Scholar]
  67. Uusimaa J, Kaarteenaho R, Paakkola T, Tuominen H, Karjalainen MK, Nadaf J, et al. NHLRC2 variants identified in patients with fibrosis, neurodegeneration, and cerebral angiomatosis (FINCA): characterisation of a novel cerebropulmonary disease. Acta Neuropathol. 2018;135:727–742. doi: 10.1007/s00401-018-1817-z. [DOI] [PubMed] [Google Scholar]
  68. van Dijk KD, Berendse HW, Drukarch B, Fratantoni SA, Pham TV, Piersma SR, et al. The proteome of the locus ceruleus in Parkinson’s disease: relevance to pathogenesis. Brain Pathol. 2012;22:485–498. doi: 10.1111/j.1750-3639.2011.00540.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Wang C, Telpoukhovskaia MA, Bahr BA, Chen X, Gan L. Endo-lysosomal dysfunction: a converging mechanism in neurodegenerative diseases. Curr Opin Neurobiol. 2018;48:52–58. doi: 10.1016/J.CONB.2017.09.005. [DOI] [PubMed] [Google Scholar]
  70. White JK, Gerdin AK, Karp NA, Ryder E, Buljan M, Bussell JN, et al. Genome-wide generation and systematic phenotyping of knockout mice reveals new roles for many genes. Cell. 2013;154:452. doi: 10.1016/j.cell.2013.06.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Wollerton MC, Gooding C, Wagner EJ, Garcia-Blanco MA, Smith CWJ. Autoregulation of polypyrimidine tract binding protein by alternative splicing leading to nonsense-mediated decay. Mol Cell. 2004;13:91–100. doi: 10.1016/S1097-2765(03)00502-1. [DOI] [PubMed] [Google Scholar]
  72. Wolozin B, Ivanov P. Stress granules and neurodegeneration. Nat Rev Neurosci. 2019;20:649–666. doi: 10.1038/s41583-019-0222-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Ye Y, Shibata Y, Kikkert M, Van Voorden S, Wiertz E, Rapoport TA. Recruitment of the p97 ATPase and ubiquitin ligases to the site of retrotranslocation at the endoplasmic reticulum membrane. Proc Natl Acad Sci USA. 2005;102:14132–14138. doi: 10.1073/pnas.0505006102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Yeung ATY, Choi YH, Lee AHY, Hale C, Ponstingl H, Pickard D, et al. A genome-wide knockout screen in human macrophages idetified host factors modulating Salmonella infection. MBio. 2019 doi: 10.1128/mBio.02169-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O’Keeffe S, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34:11929–11947. doi: 10.1523/JNEUROSCI.1860-14.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Zhang Y, Sloan SA, Clarke LE, Caneda C, Plaza CA, Blumenthal PD, et al. Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. Neuron. 2016;89:37–53. doi: 10.1016/j.neuron.2015.11.013. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

10020_2020_245_MOESM1_ESM.pdf (1.7MB, pdf)

Additional file 1: Detailed description of the materials and methods, supplementary figures S1- S11, and supplementary tables S1-S6. Materials and methods include generation of FINCA mouse, used animals, genotyping, Sanger equencing, histology, blood analysis, ISH, NPC culture, 2DE-DIGE, mass spectrometry, qPCR, immunoblotting, ICC, data analysis, and statistical considerations. Fig. S1 Genotyping and Sanger sequencing of three founders obtained from microinjections of Cas9 ribonucleoprotein and ssODN into mouse zygotes. Fig. S2 SDS-PAGE immunoblotting showing decrease of NHLRC2 in different brain regions and different tissues of Nhlrc2FINCA/− mice compared to wild type mice. Fig. S3 SDS-PAGE immunoblotting comparing the amount of NHLRC2 between wildtype, homozygous Nhlrc2FINCA/FINCA and compound heterozygous Nhlrc2FINCA/− mice. Fig. S4 Representative images of Nhlrc2+/+ and Nhlrc2FINCA/− mouse lung and liver sections. Fig. S5 NPC isolation and culture. Fig. S6 Representative 2D gel of NPCs (wild type). Fig. S7 STRING network analysis of identified proteins. Fig S8 SDS-PAGE immunoblot and 2D gel immunoblotof Nhlrc2+/+ and Nhlrc2FINCA/− NPC lysates with VCP antibodies. Fig. S9 hnRNP C2 ICC image of Nhlrc2+/+ and Nhlrc2FINCA/− NPCs showing normal cellular localization. Fig. S10 SDS-PAGE immunoblotting of Nhlrc2+/+ and Nhlrc2FINCA/− cerebellum and brainstem. Fig. S11 ISH of Nhlrc2FINCA/− mouse brain. Table S1 Genotyping primers. Table S2 qPCR primers. Table S3 Genotype distribution of Nhlrc2+/+ and Nhlrc2FINCA/− mouse offspring. Table S4 Blood values of Nhlrc2+/+ and Nhlrc2FINCA/− mice. Table S5 Detailed statistical and MS data about the proteins identified from 2DE-DIGE. Table S6. qPCR results of expression levels of genes identified in 2DE-DIGE.

10020_2020_245_MOESM2_ESM.pdf (355.4KB, pdf)

Additional file 2: Unedited full images of the immunoblots for Fig. 2, Fig. 4, Fig. S2, Fig. S3, Fig S8, and Fig S10.

Data Availability Statement

Majority of the data generated or analysed during this study are included in this published article [and its additional information files]. Further information and additional datasets are available from the corresponding author on reasonable request.

Articles from Molecular Medicine are provided here courtesy of The Feinstein Institute for Medical Research at North Shore LIJ

RESOURCES